Can we count your visit with Google Analytics? No ads, no profiles. Details
CDIO
USHealth Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: cardiovascular disease remains the #1 global killer; standard lipid/CRP panels miss ~50% of first-event MI patients, creating demand for next-gen biomarker screening. Epigenetic methylation signatures are reproducible and actionable earlier than genomic SNP panels.
PrecisionCHD fills a genuine diagnostic gap; direct-to-physician commercialization avoids hospital procurement drag; AI/epigenetics narrative could command premium multiple on any revenue inflection; tiny float magnifies any catalyst.
Pre-revenue microcap burning cash with no commercial-scale traction evidence; reimbursement pathway unclear (CPT coverage risk is binary); competing against established players (Quest, LabCorp, Foundation Medicine) with vastly more distribution; dilution risk severe at sub-$10M market cap.
It reads our $CDIO data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.